Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Orquest plans autumn IDE submission for Healos collagen-based bone grafting material.

This article was originally published in The Gray Sheet

Executive Summary

ORQUEST HEALOS BONE GRAFTING MATERIAL ENTERS CLINICALS in Europe, the company says. Mountain View, California-based Orquest announced June 18 that it has commenced patient enrollment in a feasibility study evaluating use of the resorbable hydroxyapatite-coated collagen fiber material in spinal fusion procedures for patients with degenerative disc disease (DDD).
UsernamePublicRestriction

Register

MT006251

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel